|Bid||0.00 x 50000|
|Ask||0.00 x 40000|
|Day's range||103.90 - 105.95|
|52-week range||93.38 - 203.20|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||177.14|
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ST. HELIER, Jersey, October 21, 2021--Novocure announced 15 presentations on Tumor Treating Fields will be featured at the ASTRO 2021 Annual Meeting from Oct. 24 to Oct. 27 in Chicago.
In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss three stocks to consider buying if the stock market sell-off worsens. Keith Speights: We're talking and we're nearly a full week into October right now, the stock market is off to a rocky start so far this month, quite a few biotech stocks and other healthcare stocks as well are down quite a bit already.